|
Overview
Cardax Pharmaceuticals is developing proprietary small molecule therapies for large
unmet medical needs where oxidative stress and inflammation play important causative
roles - including cardiovascular disease, hepatitis, macular degeneration, and many cancers.
Most anti-inflammatory drugs have significant safety and side effect issues that
limit their utility. In contrast, the Company’s proprietary, synthetic, natural compound
derivatives represent a novel treatment approach that offers efficacy along with an outstanding
safety profile, oral bioavailability and tissue selectivity.
Utilizing Focused Drug Design (our version of "Rational Drug Development") compared to traditional
high throughput screening provides an efficient, cost effective approach to discover and develop
compounds with a much greater likelihood of clinical success.
The Company is focusing first, with its lead compound, on cardiovascular disease
where inflammation and oxidative stress are implicated. The Company has entered into a strategic
alliance with BASF for the preclinical, clinical, and commercial manufacturing of the lead compound key
intermediate. The clinical path is designed to achieve value creation by demonstrating meaningful
safety and efficacy as early and efficiently as possible in our clinical development.
This effort is being led by a highly experienced management and scientific team, and is supported by
a world class Scientific Advisory Board.
|